BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hosseini SS, Khalili S, Baradaran B, Bidar N, Shahbazi MA, Mosafer J, Hashemzaei M, Mokhtarzadeh A, Hamblin MR. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. Int J Biol Macromol 2021;167:1030-47. [PMID: 33197478 DOI: 10.1016/j.ijbiomac.2020.11.058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lai H, Han J, Fu X, Ren Y, Li Z, You F. Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. Cancers 2022;14:3774. [DOI: 10.3390/cancers14153774] [Reference Citation Analysis]
2 Mahdavi SZB, Oroojalian F, Eyvazi S, Hejazi M, Baradaran B, Pouladi N, Tohidkia MR, Mokhtarzadeh A, Muyldermans S. An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages. Int J Biol Macromol 2022;208:421-42. [PMID: 35339499 DOI: 10.1016/j.ijbiomac.2022.03.113] [Reference Citation Analysis]
3 Shen Y, Eng JS, Fajardo F, Liang L, Li C, Collins P, Tedesco D, Nolan-Stevaux O. Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway. J Immunother Cancer 2022;10:e004348. [PMID: 35296559 DOI: 10.1136/jitc-2021-004348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci 2022;9:847835. [DOI: 10.3389/fmolb.2022.847835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yu S, Wang Y, He P, Shao B, Liu F, Xiang Z, Yang T, Zeng Y, He T, Ma J, Wang X, Liu L. Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. Front Oncol 2022;12:809304. [DOI: 10.3389/fonc.2022.809304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. [PMID: 34922633 DOI: 10.1186/s40164-021-00250-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Xie Y, Xie F, Zhang L, Zhou X, Huang J, Wang F, Jin J, Zhang L, Zeng L, Zhou F. Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells. Adv Sci (Weinh) 2021;8:e2101672. [PMID: 34658167 DOI: 10.1002/advs.202101672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hernando-Calvo A, Cescon DW, Bedard PL. Novel classes of immunotherapy for breast cancer. Breast Cancer Res Treat 2021. [PMID: 34623509 DOI: 10.1007/s10549-021-06405-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Belmontes B, Sawant DV, Zhong W, Tan H, Kaul A, Aeffner F, O'Brien SA, Chun M, Noubade R, Eng J, Ma H, Muenz M, Li P, Alba BM, Thomas M, Cook K, Wang X, DeVoss J, Egen JG, Nolan-Stevaux O. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl Med 2021;13:eabd1524. [PMID: 34433637 DOI: 10.1126/scitranslmed.abd1524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Perez-Santos M, Anaya-Ruiz M, Sanchez-Esgua G, Villafaña-Diaz L, Barron-Villaverde D. Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. Pharm Pat Anal 2021;10:67-72. [PMID: 33829869 DOI: 10.4155/ppa-2020-0035] [Reference Citation Analysis]
12 Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L. The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Curr Oncol 2021;28:1077-93. [PMID: 33652996 DOI: 10.3390/curroncol28020105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
13 Nagano K, Tsutsumi Y. Phage Display Technology as a Powerful Platform for Antibody Drug Discovery. Viruses 2021;13:178. [PMID: 33504115 DOI: 10.3390/v13020178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]